

Supplementary Material

Supplementary Table 1. Patient characteristics (variables not reported in Table 1).

Predictor	Deriv.	Valid.	Test, f.	Test, I.
Total patients	1297	649	682	219
Time to critical phase or loss to follow-up				
1	75 (6%)	40 (6%)	127 (19%)	48 (22%)
2	82 (6%)	31 (5%)	41 (6%)	17 (8%)
3	89 (7%)	26 (4%)	38 (6%)	16 (7%)
4	82 (6%)	39 (6%)	34 (5%)	7 (3%)
5	84 (6%)	39 (6%)	44 (6%)	12 (5%)
6	84 (6%)	48 (7%)	34 (5%)	13 (6%)
7	87 (7%)	39 (6%)	42 (6%)	14 (6%)
≥8	714 (55%)	387 (60%)	322 (47%)	92 (42%)
Day of symptom/uncompl. phase start (relative to diagnosis)				
≤ -8	188 (14%)	91 (14%)	76 (11%)	24 (11%)
-7	68 (5%)	47 (7%)	55 (8%)	22 (10%)
-6	38 (3%)	22 (3%)	22 (3%)	11 (5%)
-5	60 (5%)	22 (3%)	27 (4%)	9 (4%)
-4	59 (5%)	14 (2%)	29 (4%)	9 (4%)
-3	71 (5%)	41 (6%)	41 (6%)	14 (6%)
-2	85 (7%)	37 (6%)	50 (7%)	17 (8%)
-1	88 (7%)	49 (8%)	49 (7%)	18 (8%)
0	367 (28%)	179 (28%)	222 (33%)	58 (26%)
≥ 1	82 (6%)	40 (6%)	10 (1%)	3 (1%)
Missing	191 (15%)	107 (16%)	101 (15%)	34 (16%)
Emergency hospital admission				
Yes	564 (43%)	245 (38%)	447 (66%)	131 (60%)
No	369 (28%)	220 (34%)	223 (33%)	84 (38%)
Missing	364 (28%)	184 (28%)	12 (2%)	4 (2%)
Month of diagnosis				
≤3/2020	653 (50%)	333 (51%)	91 (13%)	20 (9%)
4/2020	495 (38%)	238 (37%)	114 (17%)	23 (11%)
5/2020	99 (8%)	49 (8%)	29 (4%)	9 (4%)
6/2020	38 (3%)	23 (4%)	16 (2%)	4 (2%)
7/2020	12 (1%)	6 (1%)	65 (10%)	37 (17%)
8/2020	0 (0%)	0 (0%)	77 (11%)	24 (11%)
9/2020	0 (0%)	0 (0%)	85 (12%)	35 (16%)
10/2020	0 (0%)	0 (0%)	184 (27%)	59 (27%)
11/2020	0 (0%)	0 (0%)	21 (3%)	8 (4%)
Any neurologic comorbidity				
Yes	291 (22%)	145 (22%)	133 (20%)	32 (15%)
No	774 (60%)	393 (61%)	534 (78%)	182 (83%)
Missing	232 (18%)	111 (17%)	15 (2%)	5 (2%)
Hemiplegia				
Yes	31 (2%)	16 (2%)	8 (1%)	3 (1%)
No	1235 (95%)	614 (95%)	655 (96%)	211 (96%)
Missing	31 (2%)	19 (3%)	19 (3%)	5 (2%)
Dementia				
Yes	112 (9%)	65 (10%)	53 (8%)	10 (5%)
No	1153 (89%)	568 (88%)	613 (90%)	204 (93%)
Missing	32 (2%)	16 (2%)	16 (2%)	5 (2%)
Cerebrovascular disease, stroke, TIA				
Yes	128 (10%)	63 (10%)	60 (9%)	16 (7%)
No	1139 (88%)	567 (87%)	604 (89%)	198 (90%)
Missing	30 (2%)	19 (3%)	18 (3%)	5 (2%)
Movement disorder (e.g. Parkinson's disease, Dystonia, Ataxia, Tremor)				
Yes	28 (2%)	12 (2%)	0 (0%)	0 (0%)
No	1014 (78%)	511 (79%)	0 (0%)	0 (0%)
Missing	255 (20%)	126 (19%)	682 (100%)	219 (100%)
Other neurological autoimmune diseases				
Yes	5 (0%)	3 (0%)	1 (0%)	1 (0%)
No	1220 (94%)	614 (95%)	662 (97%)	213 (97%)
Missing	72 (6%)	32 (5%)	19 (3%)	5 (2%)
Other prior neurological diagnosis				
Yes	72 (6%)	35 (5%)	31 (5%)	9 (4%)
No	970 (75%)	485 (75%)	632 (93%)	205 (94%)
Missing	255 (20%)	129 (20%)	19 (3%)	5 (2%)
Myocardial infarction				
Yes	80 (6%)	43 (7%)	36 (5%)	7 (3%)
No	1169 (90%)	583 (90%)	627 (92%)	207 (95%)
Predictor	Deriv.	Valid.	Test, f.	Test, I.
Missing	48 (4%)	23 (4%)	19 (3%)	5 (2%)
Aortic stenosis				
Yes	43 (3%)	18 (3%)	14 (2%)	4 (2%)
No	1195 (92%)	600 (92%)	648 (95%)	210 (96%)
Missing	59 (5%)	31 (5%)	20 (3%)	5 (2%)
AV block				
Yes	36 (3%)	16 (2%)	11 (2%)	2 (1%)
No	1201 (93%)	603 (93%)	652 (96%)	212 (97%)
Missing	60 (5%)	30 (5%)	19 (3%)	5 (2%)
Carotid arterial disease				
Yes	37 (3%)	18 (3%)	12 (2%)	3 (1%)
No	1184 (91%)	594 (92%)	648 (95%)	211 (96%)
Missing	76 (6%)	37 (6%)	22 (3%)	5 (2%)
Chronic heart failure				
Yes	132 (10%)	75 (12%)	40 (6%)	14 (6%)
No	1116 (86%)	550 (85%)	623 (91%)	201 (92%)
Missing	49 (4%)	24 (4%)	19 (3%)	4 (2%)
Peripheral vascular disease				
Yes	59 (5%)	29 (4%)	22 (3%)	7 (3%)
No	1182 (91%)	589 (91%)	640 (94%)	207 (95%)
Missing	56 (4%)	31 (5%)	20 (3%)	5 (2%)
Hypertension				
Yes	640 (49%)	310 (48%)	306 (45%)	88 (40%)
No	638 (49%)	331 (51%)	365 (54%)	128 (58%)
Missing	19 (1%)	8 (1%)	11 (2%)	3 (1%)
Atrial fibrillation				
Yes	179 (14%)	97 (15%)	78 (11%)	17 (8%)
No	1083 (84%)	530 (82%)	585 (86%)	198 (90%)
Missing	35 (3%)	22 (3%)	19 (3%)	4 (2%)
Coronary artery disease				
Yes	190 (15%)	93 (14%)	87 (13%)	19 (9%)
No	1051 (81%)	526 (81%)	575 (84%)	195 (89%)
Missing	56 (4%)	30 (5%)	20 (3%)	5 (2%)
COPD				
Yes	73 (6%)	36 (6%)	41 (6%)	13 (6%)
No	1198 (92%)	599 (92%)	622 (91%)	200 (91%)
Missing	26 (2%)	14 (2%)	19 (3%)	6 (3%)
Asthma				
Yes	60 (5%)	29 (4%)	47 (7%)	19 (9%)
No	1209 (93%)	606 (93%)	616 (90%)	194 (89%)
Missing	28 (2%)	14 (2%)	19 (3%)	6 (3%)
Other chronic pulmonary diseases				
Yes	55 (4%)	35 (5%)	25 (4%)	9 (4%)
No	1194 (92%)	587 (90%)	638 (94%)	204 (93%)
Missing	48 (4%)	27 (4%)	19 (3%)	6 (3%)
Leukemia				
Yes	23 (2%)	10 (2%)	5 (1%)	1 (0%)
No	1241 (96%)	625 (96%)	657 (96%)	213 (97%)
Missing	33 (3%)	14 (2%)	20 (3%)	5 (2%)
Lymphoma				
Yes	39 (3%)	17 (3%)	9 (1%)	1 (0%)
No	1226 (95%)	618 (95%)	653 (96%)	213 (97%)
Missing	32 (2%)	14 (2%)	20 (3%)	5 (2%)
Solid tumor				
Yes	116 (9%)	60 (9%)	43 (6%)	13 (6%)
No	1151 (89%)	572 (88%)	618 (91%)	200 (91%)
Missing	30 (2%)	17 (3%)	21 (3%)	6 (3%)
Solid tumor, metastasized				
Yes	57 (4%)	21 (3%)	17 (2%)	4 (2%)
No	1205 (93%)	611 (94%)	646 (95%)	210 (96%)
Missing	35 (3%)	17 (3%)	19 (3%)	5 (2%)
Stem cell transplantation				
Yes	10 (1%)	7 (1%)	0 (0%)	0 (0%)
No	1253 (97%)	629 (97%)	663 (97%)	214 (98%)
Missing	34 (3%)	13 (2%)	19 (3%)	5 (2%)
Connective tissue disease				
Yes	15 (1%)	4 (1%)	5 (1%)	1 (0%)
No	1250 (96%)	630 (97%)	659 (97%)	213 (97%)
Missing	32 (2%)	15 (2%)	18 (3%)	5 (2%)
Peptic ulcer disease				

Predictor	Deriv.	Valid.	Test, f.	Test, l.
Yes	39 (3%)	17 (3%)	5 (1%)	1 (0%)
No	1226 (95%)	616 (95%)	657 (96%)	213 (97%)
Missing	32 (2%)	16 (2%)	20 (3%)	5 (2%)
Chronic liver disease				
Yes	29 (2%)	13 (2%)	8 (1%)	3 (1%)
No	1236 (95%)	622 (96%)	653 (96%)	211 (96%)
Missing	32 (2%)	14 (2%)	21 (3%)	5 (2%)
Liver cirrhosis				
Yes	15 (1%)	5 (1%)	6 (1%)	1 (0%)
No	1252 (97%)	629 (97%)	656 (96%)	213 (97%)
Missing	30 (2%)	15 (2%)	20 (3%)	5 (2%)
Diabetes, no end-organ damage				
Yes	164 (13%)	81 (12%)	101 (15%)	39 (18%)
No	1106 (85%)	554 (85%)	564 (83%)	177 (81%)
Missing	27 (2%)	14 (2%)	17 (2%)	3 (1%)
Diabetes, with end-organ damage				
Yes	90 (7%)	47 (7%)	35 (5%)	4 (2%)
No	1177 (91%)	587 (90%)	626 (92%)	210 (96%)
Missing	30 (2%)	15 (2%)	21 (3%)	5 (2%)
Acute kidney injury				
Yes	59 (5%)	33 (5%)	26 (4%)	5 (2%)
No	888 (68%)	445 (69%)	650 (95%)	214 (98%)
Missing	350 (27%)	171 (26%)	6 (1%)	0 (0%)
Chronic kidney disease				
Yes	206 (16%)	97 (15%)	77 (11%)	17 (8%)
No	1060 (82%)	537 (83%)	587 (86%)	197 (90%)
Missing	31 (2%)	15 (2%)	18 (3%)	5 (2%)
On dialysis				
Yes	26 (2%)	18 (3%)	14 (2%)	6 (3%)
No	1241 (96%)	617 (95%)	648 (95%)	208 (95%)
Missing	30 (2%)	14 (2%)	20 (3%)	5 (2%)
Organ transplantation				
Yes	26 (2%)	18 (3%)	10 (1%)	4 (2%)
No	1240 (96%)	617 (95%)	653 (96%)	210 (96%)
Missing	31 (2%)	14 (2%)	19 (3%)	5 (2%)
Rheumatic disease				
Yes	46 (4%)	22 (3%)	23 (3%)	5 (2%)
No	1187 (92%)	598 (92%)	641 (94%)	209 (95%)
Missing	64 (5%)	29 (4%)	18 (3%)	5 (2%)
Stage of heart failure (NYHA) at diagnosis				
None	775 (60%)	376 (58%)	501 (73%)	175 (80%)
NYHA I	48 (4%)	22 (3%)	9 (1%)	3 (1%)
NYHA II	35 (3%)	28 (4%)	18 (3%)	8 (4%)
NYHA III	34 (3%)	17 (3%)	24 (4%)	7 (3%)
NYHA IV	10 (1%)	5 (1%)	5 (1%)	2 (1%)
Missing	395 (30%)	201 (31%)	125 (18%)	24 (11%)
Asymptomatic (sympt.)				
Not quoted	892 (69%)	444 (68%)	503 (74%)	167 (76%)
Quoted	147 (11%)	73 (11%)	77 (11%)	29 (13%)
Missing	258 (20%)	132 (20%)	102 (15%)	23 (11%)
Runny nose (sympt.)				
Not quoted	955 (74%)	481 (74%)	514 (75%)	177 (81%)
Quoted	34 (3%)	21 (3%)	30 (4%)	5 (2%)
Missing	308 (24%)	147 (23%)	138 (20%)	37 (17%)
Sore throat (sympt.)				
Not quoted	935 (72%)	471 (73%)	490 (72%)	170 (78%)
Quoted	59 (5%)	34 (5%)	58 (9%)	14 (6%)
Missing	303 (23%)	144 (22%)	134 (20%)	35 (16%)
Dry cough (sympt.)				
Not quoted	658 (51%)	331 (51%)	353 (52%)	116 (53%)
Quoted	394 (30%)	190 (29%)	260 (38%)	90 (41%)
Missing	245 (19%)	128 (20%)	69 (10%)	13 (6%)
Productive cough (sympt.)				
Not quoted	950 (73%)	471 (73%)	508 (74%)	174 (79%)
Quoted	68 (5%)	34 (5%)	60 (9%)	19 (9%)
Missing	279 (22%)	144 (22%)	114 (17%)	26 (12%)
Wheezing (sympt.)				
Not quoted	993 (77%)	498 (77%)	530 (78%)	178 (81%)
Quoted	16 (1%)	3 (0%)	10 (1%)	4 (2%)
Missing	288 (22%)	148 (23%)	142 (21%)	37 (17%)
Dyspnoe (sympt.)				
Not quoted	720 (56%)	359 (55%)	377 (55%)	130 (59%)
Quoted	287 (22%)	143 (22%)	238 (35%)	75 (34%)

Predictor	Deriv.	Valid.	Test, f.	Test, l.
Missing	290 (22%)	147 (23%)	67 (10%)	14 (6%)
Palpitations (sympt.)				
Not quoted	989 (76%)	494 (76%)	534 (78%)	176 (80%)
Quoted	15 (1%)	10 (2%)	4 (1%)	2 (1%)
Missing	293 (23%)	145 (22%)	144 (21%)	41 (19%)
Diarrhea (sympt.)				
Not quoted	909 (70%)	461 (71%)	502 (74%)	170 (78%)
Quoted	110 (8%)	49 (8%)	69 (10%)	23 (11%)
Missing	278 (21%)	139 (21%)	111 (16%)	26 (12%)
Nausea/emesis (sympt.)				
Not quoted	915 (71%)	458 (71%)	501 (73%)	167 (76%)
Quoted	98 (8%)	53 (8%)	61 (9%)	18 (8%)
Missing	284 (22%)	138 (21%)	120 (18%)	34 (16%)
Muscle aches (sympt.)				
Not quoted	883 (68%)	445 (69%)	470 (69%)	151 (69%)
Quoted	124 (10%)	58 (9%)	77 (11%)	31 (14%)
Missing	290 (22%)	146 (22%)	135 (20%)	37 (17%)
Muscle weakness (sympt.)				
Not quoted	895 (69%)	462 (71%)	454 (67%)	147 (67%)
Quoted	109 (8%)	41 (6%)	90 (13%)	35 (16%)
Missing	293 (23%)	146 (22%)	138 (20%)	37 (17%)
Fever (sympt.)				
Not quoted	580 (45%)	287 (44%)	300 (44%)	101 (46%)
Quoted	461 (36%)	237 (37%)	326 (48%)	103 (47%)
Missing	256 (20%)	125 (19%)	56 (8%)	15 (7%)
Delirium (sympt.)				
Not quoted	983 (76%)	493 (76%)	547 (80%)	193 (88%)
Quoted	23 (2%)	10 (2%)	9 (1%)	3 (1%)
Missing	291 (22%)	146 (22%)	126 (18%)	23 (11%)
Excessive tiredness (sympt.)				
Not quoted	808 (62%)	414 (64%)	450 (66%)	144 (66%)
Quoted	210 (16%)	94 (14%)	120 (18%)	50 (23%)
Missing	279 (22%)	141 (22%)	112 (16%)	25 (11%)
Headache (sympt.)				
Not quoted	890 (69%)	458 (71%)	462 (68%)	157 (72%)
Quoted	109 (8%)	48 (7%)	84 (12%)	25 (11%)
Missing	298 (23%)	143 (22%)	136 (20%)	37 (17%)
Meningism (sympt.)				
Not quoted	999 (77%)	501 (77%)	538 (79%)	177 (81%)
Quoted	5 (0%)	2 (0%)	0 (0%)	0 (0%)
Missing	293 (23%)	146 (22%)	144 (21%)	42 (19%)
Smelling disorder (sympt.)				
Not quoted	941 (73%)	486 (75%)	503 (74%)	172 (79%)
Quoted	43 (3%)	12 (2%)	26 (4%)	6 (3%)
Missing	313 (24%)	151 (23%)	153 (22%)	41 (19%)
Tasting disorder (sympt.)				
Not quoted	926 (71%)	478 (74%)	480 (70%)	164 (75%)
Quoted	58 (4%)	20 (3%)	58 (9%)	14 (6%)
Missing	313 (24%)	151 (23%)	144 (21%)	41 (19%)
Other neurological symptoms				
Not quoted	959 (74%)	480 (74%)	523 (77%)	173 (79%)
Quoted	56 (4%)	21 (3%)	14 (2%)	6 (3%)
Missing	282 (22%)	148 (23%)	145 (21%)	40 (18%)
Red eye (sympt.)				
Not quoted	987 (76%)	498 (77%)	533 (78%)	178 (81%)
Quoted	9 (1%)	6 (1%)	0 (0%)	0 (0%)
Missing	301 (23%)	145 (22%)	149 (22%)	41 (19%)
Pulse				
< 60 bpm	39 (3%)	16 (2%)	20 (3%)	7 (3%)
60 - 89 bpm	717 (55%)	359 (55%)	372 (55%)	124 (57%)
90 - 119 bpm	366 (28%)	180 (28%)	205 (30%)	67 (31%)
> 119 bpm	50 (4%)	26 (4%)	33 (5%)	10 (5%)
Missing	125 (10%)	68 (10%)	52 (8%)	11 (5%)
SBP				
< 80 mmHg	5 (0%)	3 (0%)	4 (1%)	1 (0%)
80 - 99 mmHg	41 (3%)	32 (5%)	20 (3%)	6 (3%)
100 - 119 mmHg	282 (22%)	142 (22%)	124 (18%)	37 (17%)
120 - 139 mmHg	471 (36%)	223 (34%)	255 (37%)	89 (41%)

Predictor	Deriv.	Valid.	Test, f.	Test, l.
140 - 179 mmHg	352 (27%)	168 (26%)	210 (31%)	72 (33%)
> 179 mmHg	33 (3%)	17 (3%)	20 (3%)	4 (2%)
Missing	113 (9%)	64 (10%)	49 (7%)	10 (5%)
DBP				
< 40 mmHg	3 (0%)	3 (0%)	0 (0%)	0 (0%)
40 - 59 mmHg	118 (9%)	60 (9%)	36 (5%)	9 (4%)
60 - 89 mmHg	861 (66%)	441 (68%)	480 (70%)	162 (74%)
90 - 109 mmHg	188 (14%)	71 (11%)	103 (15%)	32 (15%)
> 109 mmHg	11 (1%)	7 (1%)	14 (2%)	6 (3%)
Missing	116 (9%)	67 (10%)	49 (7%)	10 (5%)
SO2				
< 60%	10 (1%)	1 (0%)	2 (0%)	1 (0%)
60 - 69%	5 (0%)	2 (0%)	1 (0%)	0 (0%)
70 - 79%	14 (1%)	11 (2%)	2 (0%)	1 (0%)
80 - 89%	124 (10%)	72 (11%)	58 (9%)	16 (7%)
90 - 95%	487 (38%)	222 (34%)	238 (35%)	67 (31%)
96 - 100%	505 (39%)	257 (40%)	317 (46%)	118 (54%)
Missing	152 (12%)	84 (13%)	64 (9%)	16 (7%)
Body temperature				
< 35.1 °C	3 (0%)	5 (1%)	0 (0%)	0 (0%)
35.1 - 37.3 °C	501 (39%)	233 (36%)	282 (41%)	96 (44%)
37.3 - 37.9 °C	232 (18%)	138 (21%)	139 (20%)	54 (25%)
38 - 38.9 °C	310 (24%)	141 (22%)	147 (22%)	36 (16%)
39 - 39.9 °C	106 (8%)	63 (10%)	54 (8%)	17 (8%)
> 39.9 °C	10 (1%)	15 (2%)	6 (1%)	1 (0%)
Missing	135 (10%)	54 (8%)	54 (8%)	15 (7%)
Respiratory rate				
< 16	199 (15%)	96 (15%)	110 (16%)	29 (13%)
16-21	411 (32%)	214 (33%)	245 (36%)	85 (39%)
22-29	211 (16%)	91 (14%)	86 (13%)	18 (8%)
> 29	45 (3%)	29 (4%)	41 (6%)	11 (5%)
Missing	431 (33%)	219 (34%)	200 (29%)	76 (35%)
BMI				
< 18.5 kg/m ²	23 (2%)	17 (3%)	13 (2%)	3 (1%)
18.5 - 24.9 kg/m ²	301 (23%)	152 (23%)	118 (17%)	50 (23%)
25 - 29.9 kg/m ²	288 (22%)	135 (21%)	159 (23%)	55 (25%)
30 - 34.9 kg/m ²	121 (9%)	70 (11%)	96 (14%)	42 (19%)
> 34.9 kg/m ²	55 (4%)	23 (4%)	43 (6%)	15 (7%)
Missing	509 (39%)	252 (39%)	253 (37%)	54 (25%)
ACE-inhibitors				
Yes	238 (18%)	122 (19%)	147 (22%)	39 (18%)
No	1022 (79%)	510 (79%)	507 (74%)	169 (77%)
Missing	37 (3%)	17 (3%)	28 (4%)	11 (5%)
AT1-RB				
Yes	217 (17%)	108 (17%)	98 (14%)	29 (13%)
No	1025 (79%)	524 (81%)	544 (80%)	178 (81%)
Missing	55 (4%)	17 (3%)	40 (6%)	12 (5%)
Statines				
Yes	253 (20%)	138 (21%)	136 (20%)	34 (16%)
No	770 (59%)	378 (58%)	512 (75%)	174 (79%)
Missing	274 (21%)	133 (20%)	34 (5%)	11 (5%)
Ibuprofen				
Yes	47 (4%)	28 (4%)	29 (4%)	5 (2%)
No	1129 (87%)	566 (87%)	586 (86%)	194 (89%)
Missing	121 (9%)	55 (8%)	67 (10%)	20 (9%)
Immunosuppressants				
Yes	131 (10%)	71 (11%)	51 (7%)	19 (9%)
No	1014 (78%)	515 (79%)	571 (84%)	194 (89%)
Missing	152 (12%)	63 (10%)	60 (9%)	6 (3%)
Complementary/integrative medicine				
Yes	18 (1%)	4 (1%)	12 (2%)	0 (0%)
No	861 (66%)	438 (67%)	593 (87%)	213 (97%)

Predictor	Deriv.	Valid.	Test, f.	Test, l.
Missing	418 (32%)	207 (32%)	77 (11%)	6 (3%)
Smoking status				
1-10 pack years	22 (2%)	5 (1%)	8 (1%)	3 (1%)
11-20 pack years	14 (1%)	8 (1%)	6 (1%)	2 (1%)
>21 pack years	34 (3%)	13 (2%)	9 (1%)	2 (1%)
Nonsmoker	468 (36%)	255 (39%)	222 (33%)	84 (38%)
Former smoker	103 (8%)	57 (9%)	50 (7%)	13 (6%)
Smoker, unknown	21 (2%)	14 (2%)	24 (4%)	9 (4%)
Missing	635 (49%)	297 (46%)	363 (53%)	106 (48%)
IgG-titer positive				
Yes	675 (52%)	349 (54%)	645 (95%)	192 (88%)
No	608 (47%)	293 (45%)	0 (0%)	0 (0%)
51	0 (0%)	0 (0%)	15 (2%)	12 (5%)
Missing	14 (1%)	7 (1%)	22 (3%)	15 (7%)
AST				
< LLN	2 (0%)	5 (1%)	9 (1%)	1 (0%)
Normal (LLN - ULN)	714 (55%)	336 (52%)	367 (54%)	139 (63%)
> ULN ≤ 2x ULN	283 (22%)	160 (25%)	133 (20%)	60 (27%)
> 2x ULN ≤ 5x ULN	73 (6%)	46 (7%)	33 (5%)	12 (5%)
> 5x ULN ≤ 10x ULN	8 (1%)	3 (0%)	3 (0%)	0 (0%)
Missing	217 (17%)	99 (15%)	137 (20%)	7 (3%)
ALT				
< LLN	7 (1%)	8 (1%)	9 (1%)	2 (1%)
Normal (LLN - ULN)	859 (66%)	416 (64%)	470 (69%)	162 (74%)
> ULN ≤ 2x ULN	220 (17%)	108 (17%)	100 (15%)	38 (17%)
> 2x ULN ≤ 5x ULN	42 (3%)	34 (5%)	31 (5%)	10 (5%)
> 5x ULN ≤ 10x ULN	8 (1%)	6 (1%)	5 (1%)	1 (0%)
Missing	161 (12%)	77 (12%)	67 (10%)	6 (3%)
Gamma-GT				
Normal (LLN - ULN)	678 (52%)	349 (54%)	387 (57%)	136 (62%)
> ULN ≤ 2x ULN	222 (17%)	126 (19%)	108 (16%)	41 (19%)
> 2x ULN ≤ 5x ULN	106 (8%)	56 (9%)	47 (7%)	25 (11%)
> 5x ULN ≤ 10x ULN	34 (3%)	8 (1%)	15 (2%)	3 (1%)
> 10x ULN	0 (0%)	0 (0%)	9 (1%)	1 (0%)
Missing	257 (20%)	110 (17%)	116 (17%)	13 (6%)
Bilirubine				
< LLN	7 (1%)	7 (1%)	14 (2%)	2 (1%)
Normal (LLN - ULN)	928 (72%)	470 (72%)	516 (76%)	196 (89%)
> ULN ≤ 2x ULN	50 (4%)	31 (5%)	41 (6%)	12 (5%)
> 2x ULN ≤ 5x ULN	9 (1%)	4 (1%)	5 (1%)	0 (0%)
Missing	303 (23%)	137 (21%)	106 (16%)	9 (4%)
Lipase				
< LLN	5 (0%)	2 (0%)	12 (2%)	4 (2%)
Normal (LLN - ULN)	463 (36%)	223 (34%)	342 (50%)	152 (69%)
> ULN ≤ 2x ULN	96 (7%)	51 (8%)	49 (7%)	15 (7%)
> 2x ULN ≤ 5x ULN	11 (1%)	13 (2%)	8 (1%)	1 (0%)
Missing	722 (56%)	360 (55%)	271 (40%)	47 (21%)
Troponine T				
< LLN	7 (1%)	8 (1%)	14 (2%)	8 (4%)

Predictor	Deriv.	Valid.	Test, f.	Test, l.
Normal (LLN - ULN)	431 (33%)	221 (34%)	250 (37%)	126 (58%)
> ULN ≤ 2x ULN	84 (6%)	43 (7%)	49 (7%)	24 (11%)
> 2x ULN ≤ 5x ULN	57 (4%)	28 (4%)	43 (6%)	16 (7%)
> 5x ULN ≤ 10x ULN	18 (1%)	12 (2%)	12 (2%)	1 (0%)
> 10x ULN ≤ 20x ULN	10 (1%)	7 (1%)	4 (1%)	2 (1%)
> 20x ULN	3 (0%)	4 (1%)	6 (1%)	1 (0%)
Missing	687 (53%)	326 (50%)	304 (45%)	41 (19%)
Creatinine				
< LLN	15 (1%)	13 (2%)	32 (5%)	6 (3%)
Normal (LLN - ULN)	918 (71%)	443 (68%)	477 (70%)	174 (79%)
> ULN ≤ 2x ULN	257 (20%)	140 (22%)	122 (18%)	27 (12%)
> 2x ULN ≤ 5x ULN	69 (5%)	28 (4%)	26 (4%)	4 (2%)
> 5x ULN ≤ 20x ULN	12 (1%)	10 (2%)	12 (2%)	7 (3%)
Missing	26 (2%)	15 (2%)	13 (2%)	1 (0%)
Leukocytes				
< 1,000 /μL	6 (0%)	5 (1%)	3 (0%)	1 (0%)
1,000 - 3999 /μL	234 (18%)	116 (18%)	105 (15%)	35 (16%)
4,000 - 7,999 /μL	742 (57%)	365 (56%)	386 (57%)	132 (60%)
8,000 - 11,999 /μL	224 (17%)	113 (17%)	124 (18%)	38 (17%)
12,000 - 15,999 /μL	43 (3%)	27 (4%)	34 (5%)	8 (4%)
16,000 - 19,999 /μL	22 (2%)	10 (2%)	10 (1%)	0 (0%)
≥ 20,000 /μL	15 (1%)	10 (2%)	14 (2%)	4 (2%)
Missing	11 (1%)	3 (0%)	6 (1%)	1 (0%)
Platelets				
< 10,000 /μL	7 (1%)	2 (0%)	3 (0%)	1 (0%)
10,000 - 49,999 /μL	22 (2%)	9 (1%)	7 (1%)	4 (2%)
50,000 - 119,999 /μL	121 (9%)	64 (10%)	59 (9%)	18 (8%)
120,000 - 449,999 /μL	1084 (84%)	554 (85%)	579 (85%)	193 (88%)
450,000 - 799,000 /μL	29 (2%)	12 (2%)	15 (2%)	1 (0%)
Missing	34 (3%)	8 (1%)	19 (3%)	2 (1%)
Hemoglobin				
< 6 g/dL	6 (0%)	3 (0%)	0 (0%)	0 (0%)
6 - 7.9 g/dL	40 (3%)	26 (4%)	14 (2%)	4 (2%)
8 - 9.9 g/dL	115 (9%)	48 (7%)	40 (6%)	13 (6%)
10 - 11.9 g/dL	243 (19%)	109 (17%)	137 (20%)	37 (17%)
12 - 14.9 g/dL	677 (52%)	364 (56%)	375 (55%)	132 (60%)
≥ 15 g/dL	197 (15%)	94 (14%)	107 (16%)	32 (15%)
Missing	19 (1%)	5 (1%)	9 (1%)	1 (0%)
Areas of consolidation (CT)				
Not quoted	521 (40%)	278 (43%)	428 (63%)	127 (58%)
Quoted	216 (17%)	103 (16%)	115 (17%)	55 (25%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Crazy paving pattern (CT)				
Not quoted	656 (51%)	332 (51%)	513 (75%)	165 (75%)
Quoted	37 (3%)	29 (4%)	30 (4%)	17 (8%)
Missing	604 (47%)	288 (44%)	139 (20%)	37 (17%)
Ground glass opacities (CT)				
Not quoted	376 (29%)	208 (32%)	329 (48%)	70 (32%)
Quoted	361 (28%)	173 (27%)	214 (31%)	112 (51%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Interlobular septal thickening (CT)				
Not quoted	664 (51%)	348 (54%)	529 (78%)	174 (79%)
Quoted	29 (2%)	13 (2%)	14 (2%)	8 (4%)

Predictor	Deriv.	Valid.	Test, f.	Test, l.
Missing	604 (47%)	288 (44%)	139 (20%)	37 (17%)
Nodular lesions (CT)				
Not quoted	707 (55%)	364 (56%)	521 (76%)	164 (75%)
Quoted	30 (2%)	17 (3%)	22 (3%)	18 (8%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Pleural effusion (CT)				
Not quoted	686 (53%)	354 (55%)	509 (75%)	170 (78%)
Quoted	51 (4%)	27 (4%)	34 (5%)	12 (5%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
Normal (CT)				
Not quoted	679 (52%)	337 (52%)	487 (71%)	168 (77%)
Quoted	58 (4%)	44 (7%)	56 (8%)	14 (6%)
Missing	560 (43%)	268 (41%)	139 (20%)	37 (17%)
MDRO colonization				
Yes	55 (4%)	19 (3%)	16 (2%)	6 (3%)
No	748 (58%)	395 (61%)	0 (0%)	0 (0%)
Missing	494 (38%)	235 (36%)	666 (98%)	213 (97%)

Abbreviations: ACE, angiotensin-converting-enzyme; AT1-RB, angiotensin II receptor type 1 antagonists; AV, atrioventricular; BMI, body mass index; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; CT, computed tomography; DBP, diastolic blood pressure; LLN, lower limit of normal; MDRO, multidrug-resistant organism; NYHA, New York Heart Association functional classification; SBP, systolic blood pressure; sO₂, oxygen saturation (%); sympt., variable describes whether a COVID-19 symptom is present at diagnosis; TIA, transient ischemic attack; ULN, upper limit of normal.


Supplementary Table 2. Summary of the predictive performances of Random Survival Forest and Cox models in comparison to the five variable score.

Selection	Model	N pr.	C-index (imp. range)	
			Derivation	Validation
All pr.	RSF	105	0.78 (0.78-0.78)	0.78 (0.77-0.78)
	Cox ridge	105	0.83 (0.81-0.83)	0.77 (0.77-0.77)
RSF Boruta	RSF	24	0.79 (0.79-0.80)	0.77 (0.76-0.77)
	Cox ridge	24	0.82 (0.81-0.82)	0.77 (0.77-0.77)
RF Boruta	RSF	5	0.74 (0.73-0.75)	0.73 (0.72-0.74)
	Cox ridge	5	0.76 (0.76-0.76)	0.76 (0.76-0.77)
	Binomial ridge	5	0.76 (0.76-0.76)	0.76 (0.76-0.77)
	Score	5	0.76 (0.76-0.76)	0.76 (0.76-0.77)
			95%CI, 0.73-0.79	95%CI, 0.73-0.80
	Validation on full test set			0.80 (0.80-0.81)
				95%CI, 0.76-0.84
	Validation on limited test set			0.81 (0.81-0.81)
				95%CI, 0.74-0.87


Initial derivation and validation analyses were performed on the respective datasets (n=1297 and 649, respectively) as summarized in Figure 2. As indicated, the final score was additionally independently validated on the full and the limited test sets (n=675 and 218, as described in Figure 2).

Indicated are the median values and the full range for the imputed datasets (in brackets). Harrell's C-indices were calculated using a time to event variable (as summarized in Supplementary Figure 1) in addition to the outcome. 95% confidence intervals (95%CI) were calculated for score predictions using bootstrapping with equal contributions of the imputed datasets.


Abbreviations: AUC, area under the receiver operating characteristic (ROC) curve; C-index, concordance index; imp., imputation; N pr., number of predictors in the model; pr., predictors; RSF, random survival forest.



Supplementary Figure 1. Summary of the selected variables in the RF Boruta (A) and RSF Boruta (B) approaches. Indicated are the medians and interquartile ranges of variable importance obtained during the respective run of Boruta selection. Abbreviations: sO₂, blood oxygen saturation; LDH, lactate dehydrogenase; AF, atrial fibrillation; AKI, acute kidney injury; AVB, atrioventricular block; CKD, chronic kidney disease; BMI, body mass index; CV, cardiovascular.



Supplementary Figure 2. Absolute risks for an event within 7 days of diagnosis or for all events for the indicated validation/test datasets. Lines represent mean predicted risk by a model calibrated on the derivation dataset. Dots represent observed absolute risk in the respective cohorts. Ranges indicate CI 95%.



Supplementary Figure 3. Score calibration results for event risk within 7 days of diagnosis (left panels) or for all events (right panels). Predictions for the indicated datasets were calculated with models calibrated on the derivation dataset. Solid lines represent optimal calibration. Ranges indicate CI 95%.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2-3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	3 ¹
		(b) For matched studies, give matching criteria and number of exposed and unexposed	n.a.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3 ¹ , T.1, S.T.1
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3 ¹
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	3
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	3-4
		(b) Describe any methods used to examine subgroups and interactions	n.a.
		(c) Explain how missing data were addressed	4
		(d) If applicable, explain how loss to follow-up was addressed	4
		(e) Describe any sensitivity analyses	F. 3
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	3, F.2
		(b) Give reasons for non-participation at each stage	3, F.2
		(c) Consider use of a flow diagram	F.2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	T.1, S.T.1
		(b) Indicate number of participants with missing data for each variable of interest	T.1, S.T.1
		(c) Summarise follow-up time (eg, average and total amount)	S.T.1
Outcome data	15*	Report numbers of outcome events or summary measures over time	T.1

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	T.2, T.3, T.5 T. 1 S.T.1 S.F.2
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	F. 3, S.F.3
Discussion			
Key results	18	Summarise key results with reference to study objectives	6-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8-9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	7-9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	9

*Give information separately for exposed and unexposed groups.

Abbreviations: F., figure; T., table; S., supplementary.

¹We additionally reference a previous publications from the LEOSS group which reports on the study design in further detail: Jakob et al., First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)”. Infection 2020.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.